Abacus Planning Group’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.03M | Buy |
2,527
+58
| +2% | +$59.3K | 0.37% | 36 |
|
|
2026
Q1 | $2.27M | Sell |
2,469
-126
| -5% | -$128K | 0.31% | 44 |
|
|
2025
Q4 | $2.79M | Buy |
2,595
+116
| +5% | +$111K | 0.37% | 38 |
|
|
2025
Q3 | $1.89M | Buy |
2,479
+48
| +2% | +$35.7K | 0.26% | 54 |
|
|
2025
Q2 | $1.9M | Sell |
2,431
-57
| -2% | -$44.3K | 0.28% | 50 |
|
|
2025
Q1 | $2.06M | Buy |
2,488
+79
| +3% | +$65.7K | 0.36% | 40 |
|
|
2024
Q4 | $1.86M | Buy |
2,409
+43
| +2% | +$35.6K | 0.33% | 42 |
|
|
2024
Q3 | $2.1M | Sell |
2,366
-107
| -4% | -$96.2K | 0.37% | 38 |
|
|
2024
Q2 | $2.24M | Buy |
2,473
+596
| +32% | +$477K | 0.43% | 32 |
|
|
2024
Q1 | $1.46M | Sell |
1,877
-84
| -4% | -$59.8K | 0.29% | 47 |
|
|
2023
Q4 | $1.14M | Sell |
1,961
-20
| -1% | -$11.7K | 0.24% | 59 |
|
|
2023
Q3 | $1.06M | Buy |
1,981
+89
| +5% | +$45.9K | 0.26% | 61 |
|
|
2023
Q2 | $887K | Buy |
1,892
+90
| +5% | +$37.7K | 0.21% | 73 |
|
|
2023
Q1 | $619K | Sell |
1,802
-221
| -11% | -$74.5K | 0.16% | 93 |
|
|
2022
Q4 | $740K | Buy |
2,023
+221
| +12% | +$78.4K | 0.2% | 78 |
|
|
2022
Q3 | $583K | Sell |
1,802
-25
| -1% | -$7.92K | 0.18% | 82 |
|
|
2022
Q2 | $592K | Sell |
1,827
-125
| -6% | -$37.5K | 0.17% | 89 |
|
|
2022
Q1 | $559K | Sell |
1,952
-18
| -0.9% | -$4.63K | 0.15% | 105 |
|
|
2021
Q4 | $544K | Buy |
1,970
+91
| +5% | +$23.1K | 0.15% | 104 |
|
|
2021
Q3 | $434K | Buy |
1,879
+143
| +8% | +$35.3K | 0.14% | 108 |
|
|
2021
Q2 | $398K | Sell |
1,736
-34
| -2% | -$6.83K | 0.12% | 116 |
|
|
2021
Q1 | $331K | Buy |
1,770
+195
| +12% | +$38.1K | 0.11% | 128 |
|
|
2020
Q4 | $266K | Hold |
1,575
| – | – | 0.08% | 141 |
|
|
2020
Q3 | $233K | Hold |
1,575
| – | – | 0.09% | 136 |
|
|
2020
Q2 | $259K | Hold |
1,575
| – | – | 0.11% | 127 |
|
|
2020
Q1 | $218K | Hold |
1,575
| – | – | 0.11% | 130 |
|
|
2019
Q4 | $207K | Buy |
+1,575
| New | +$183K | 0.1% | 157 |
|
|
2019
Q2 | – | Sell |
-1,575
| Closed | -$204K | – | 172 |
|
|
2019
Q1 | $204K | Sell |
1,575
-875
| -36% | -$106K | 0.13% | 142 |
|
|
2018
Q4 | $284K | Hold |
2,450
| – | – | 0.22% | 105 |
|
|
2018
Q3 | $262K | Buy |
+2,450
| New | +$245K | 0.18% | 117 |
|
Other funds holding LLY
Abacus Planning Group's LLY Position: Q2 2026 in Review
Abacus Planning Group increased its Eli Lilly (LLY) stake by 2.3% in Q2 2026, buying an estimated $59.3K and bringing the position to 2,527 shares worth $3.03M. The position accounts for 0.37% of the portfolio, ranked #36.
Abacus Planning Group first reported a position in LLY in Q3 2018 and has held it in 30 quarters since. 4,637 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Abacus Planning Group held 2,527 shares of Eli Lilly worth $3.03M as of Q2 2026.
- Abacus Planning Group bought 58 Eli Lilly shares in Q2 2026, an estimated $59.3K.
- Eli Lilly made up 0.37% of Abacus Planning Group's portfolio in Q2 2026, its #36 holding.
- Abacus Planning Group first reported a position in Eli Lilly in Q3 2018 and has held it in 30 quarters since.
- 4,637 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Abacus Planning Group's 13F filing for Q2 2026, filed 20 Jul 2026.